Cue Biopharma, Inc.
NASDAQCUE just had its biggest week in recent memory — and the catalyst wasn't a trial readout. The small-cap biotech announced a $30 million private placement, licensed a clinical-stage dual-mechanism anti-IgE antibody (Ascendant-221) from Ascendant Health Sciences in a deal valued up to roughly $691.5 million, and named Shao-Lee Lin M.D., Ph.D. as its new CEO, President, and Board…
CUE short interest utilization hits 93.69%, a 52-week high, as borrowed shares near full deployment amid recent volatility.
Short interest % of float, cost to borrow, utilization, and put/call ratio for CUE are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 6 May 2026
CUE just had its biggest week in recent memory — and the catalyst wasn't a trial readout. The small-cap biotech announced a $30 million private placement, licensed a clinical-stage dual-mechanism anti-IgE antibody…
Short sellers in CUE — Cue Biopharma — have retreated sharply. They left behind a lending market under real strain. Short interest collapsed 83% in one week, falling to just 1.1% of free float. That rapid exit drove…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CUE — free to start on ORTEX.
Sign up for free →Open CUE on ORTEX